See more : ParaZero Technologies Ltd. (PRZO) Income Statement Analysis – Financial Results
Complete financial analysis of Carisma Therapeutics, Inc. (CARM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carisma Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Earth Infinity Co.Ltd. (7692.T) Income Statement Analysis – Financial Results
- Shekhawati Poly-Yarn Limited (SPYL.BO) Income Statement Analysis – Financial Results
- Regencell Bioscience Holdings Limited (RGC) Income Statement Analysis – Financial Results
- Turtle Beach Corporation (0ZNF.L) Income Statement Analysis – Financial Results
- Bannari Amman Sugars Limited (BANARISUG.NS) Income Statement Analysis – Financial Results
Carisma Therapeutics, Inc. (CARM)
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.92M | 9.83M | 26.54M | 11.24M | 0.00 | 0.00 | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Cost of Revenue | 74.13M | 6.09M | 85.00K | 0.00 | 219.00K | 208.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -59.21M | 3.74M | 26.46M | 11.24M | -219.00K | -208.00K | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Gross Profit Ratio | -396.85% | 38.07% | 99.68% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 74.13M | 56.62M | 34.39M | 23.29M | 24.44M | 13.87M | 12.23M | 12.20M | 25.97M | 26.70M | 13.79M | 15.26M | 9.41M |
| General & Administrative | 29.53M | 9.38M | 6.41M | 5.09M | 12.21M | 11.62M | 8.07M | 14.74M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Selling & Marketing | 0.00 | 30.41M | 0.00 | 0.00 | 0.00 | 0.00 | -170.00K | -3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.53M | 3.29M | 6.41M | 5.09M | 12.21M | 11.62M | 7.90M | 11.44M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 103.65M | 59.91M | 40.79M | 28.38M | 36.65M | 25.49M | 20.13M | 23.64M | 35.82M | 35.17M | 17.81M | 19.48M | 12.68M |
| Cost & Expenses | 103.65M | 66.00M | 40.79M | 28.38M | 36.87M | 25.70M | 20.41M | 23.82M | 36.19M | 35.17M | 17.81M | 19.48M | 12.68M |
| Interest Income | 1.94M | 1.85M | 10.00K | 29.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 247.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Depreciation & Amortization | 2.84M | 6.09M | 85.00K | 122.00K | 219.00K | 208.00K | 285.00K | 178.00K | 366.00K | 410.00K | 438.00K | 448.00K | 364.00K |
| EBITDA | -85.89M | -51.99M | -40.11M | -27.93M | -107.28M | -33.49M | -28.74M | 2.32M | -31.69M | -33.37M | -17.18M | -19.04M | -12.31M |
| EBITDA Ratio | -575.74% | -509.17% | -151.12% | -248.58% | 0.00% | 0.00% | -4,635.29% | 21.16% | -3,518.18% | -1,487.74% | -1,213.42% | 0.00% | 0.00% |
| Operating Income | -88.73M | -56.16M | -40.79M | -28.38M | -36.87M | -25.70M | -19.99M | 6.17M | -35.20M | -33.78M | -16.63M | -19.49M | -12.68M |
| Operating Income Ratio | -594.75% | -571.10% | -153.68% | -252.56% | 0.00% | 0.00% | -4,702.35% | 20.57% | -3,555.15% | -1,506.02% | -1,246.25% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.85M | -5.06M | 10.00K | 29.00K | -70.63M | -7.99M | -9.04M | -4.27M | 1.74M | -1.23M | -1.40M | -168.00K | -151.00K |
| Income Before Tax | -86.88M | -61.23M | -40.78M | -28.35M | -107.50M | -33.69M | -29.03M | 1.90M | -33.45M | -34.16M | -18.03M | -19.66M | -12.83M |
| Income Before Tax Ratio | -582.34% | -622.60% | -153.65% | -252.31% | 0.00% | 0.00% | -6,830.35% | 6.32% | -3,378.99% | -1,522.78% | -1,351.20% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.88M | -10.00K | -29.00K | 0.00 | 46.86K | 0.00 | 5.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Net Income | -86.88M | -61.23M | -40.77M | -28.32M | -107.50M | -33.69M | -29.03M | 1.89M | -33.45M | -34.53M | -19.43M | -19.83M | -12.98M |
| Net Income Ratio | -582.34% | -622.60% | -153.61% | -252.05% | 0.00% | 0.00% | -6,830.35% | 6.31% | -3,378.99% | -1,539.55% | -1,456.15% | 0.00% | 0.00% |
| EPS | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.79 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| EPS Diluted | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.74 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| Weighted Avg Shares Out | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.05M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
| Weighted Avg Shares Out (Dil) | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.09M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago.
Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to...
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman, MD, and Ira Tabas, MD, PhD PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024
PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentation at the American Association for the Study of Liver...
Carisma Therapeutics Announces Changes to its Board of Directors
Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA , July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today...
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA , June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage...
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
PHILADELPHIA , June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a...
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
Fast Track designation highlights potential for CT-0525 to address unmet need for patients with solid tumors Initial Phase 1 data expected by year-end 2024 PHILADELPHIA , June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical...
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
PHILADELPHIA , May 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a...
Source: https://incomestatements.info
Category: Stock Reports